OTLC — Oncotelic Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026
Brief: Oncotelic Therapeutics To Sell Its Necroptosis Cancer Therapy Assets To Mosaic Immunoengineering
Brief: Oncotelic Announces Initiation Of Clinical Study In Non-Small Lung Cell Cancer
Brief: Oncotelic Initiates Clinical Trials Evaluating Ot-101 Against Pediatric Gliomas
Brief: Oncotelic Awarded Barda Funding For Development Of Ot-101 For Long Covid
Brief: Oncotelic Reports Q2 2022 Compared To Q2 2021 Financial Results
Brief: Oncotelic Appoints Fatih Uckun As Chief Medical Officer
Brief: Oncotelic Initiates Phase 2 Trial Evaluating Ot-101 In Combination With Keytruda® For Mesothelioma
Brief: Oncotelic Closes Covid-19 Clinical Trial Early
Brief: Mateon Announces Initiation Of Phase 1B Clinical Trial On Ot-101/Il-2 Combination Therapy For Solid Tumors
Brief: Mateon Therapeutics And Windlas Biotech Publish Pulmoheal Clinical Data Against Covid-19
Brief: Mateon's C001- Phase 2 Study For OT-101 Against COVID-19 Gets Clearance For Patient Enrollment
Brief: Mateon Therapeutics Inc Says First Patient Enrolled This Week In Its Phase IV Study
Brief: Mateon Therapeutics Inc Says FDA Granted Pediatric Disease Designation For OXi-4503
Brief: Mateon, Asili Research Alliance Enter Partnership For Development Of Artemisinin Against Covid-19
Brief: Mateon Therapeutics Submitted Application To FDA To Study Investigational Drug For Treatment Of Covid-19
Brief: Mateon Expands Covid-19 Therapeutic Program
Brief: Mateon Provides Update On Its Rapid Antiviral Response Program Initially Targeting Covid-19
Brief: Mateon Therapeutics Announces Positive Clinical Study Results For Lead Anti-Leukemia Drug Combretastatin A1 Plus Cytarabine